Unknown Manufacturer
PRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases. These binding interactions enable the compound to modulate the function of these cells and restore the balance of the immune system.
PRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases. These binding interactions enable the compound to modulate the function of these cells and restore the balance of the immune system.
PRTX-100 aims to restore normal immune system function by selectively modulating only the B-cells that are producing pathogenic auto-antibodies, which play a role in the induction and maintenance of autoimmune diseases. PRTX-100 achieves this specificity due to its ability to bind to immunoglobulins that are of a specific lineage, namely VH3, which is also the lineage that is most prevalent in the auto-antibodies that are present in numerous autoimmune diseases.
Investigated for use/treatment in autoimmune diseases, inflammatory disorders (unspecified), rheumatoid arthritis, and thrombocytopenia.
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
